Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
CDH9 Biologics Sequence Review Report 2026: Cadherin-9 Similarity and Patent-Risk Signals
8 min read
CDH9 Biologics Sequence Review Report 2026: Cadherin-9 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CDH9 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CDHR1 Biologics Sequence Review Report 2026: Cadherin-related family member 1 Similarity and Patent-Risk Signals
8 min read
CDHR1 Biologics Sequence Review Report 2026: Cadherin-related family member 1 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CDHR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CDH7 Biologics Sequence Review Report 2026: Cadherin-7 Similarity and Patent-Risk Signals
8 min read
CDH7 Biologics Sequence Review Report 2026: Cadherin-7 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CDH7 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CDH6 Biologics Sequence Review Report 2026: Cadherin-6 Similarity and Patent-Risk Signals
8 min read
CDH6 Biologics Sequence Review Report 2026: Cadherin-6 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CDH6 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CDH26 Biologics Sequence Review Report 2026: Cadherin-like protein 26 Similarity and Patent-Risk Signals
8 min read
CDH26 Biologics Sequence Review Report 2026: Cadherin-like protein 26 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CDH26 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CDH5 Biologics Sequence Review Report 2026: Cadherin-5 Similarity and Patent-Risk Signals
8 min read
CDH5 Biologics Sequence Review Report 2026: Cadherin-5 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CDH5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CDH3 Biologics Sequence Review Report 2026: Cadherin-3 Similarity and Patent-Risk Signals
8 min read
CDH3 Biologics Sequence Review Report 2026: Cadherin-3 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CDH3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CDH24 Biologics Sequence Review Report 2026: Cadherin-24 Similarity and Patent-Risk Signals
8 min read
CDH24 Biologics Sequence Review Report 2026: Cadherin-24 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CDH24 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CDH20 Biologics Sequence Review Report 2026: Cadherin-20 Similarity and Patent-Risk Signals
8 min read
CDH20 Biologics Sequence Review Report 2026: Cadherin-20 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CDH20 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CDH19 Biologics Sequence Review Report 2026: Cadherin-19 Similarity and Patent-Risk Signals
8 min read
CDH19 Biologics Sequence Review Report 2026: Cadherin-19 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CDH19 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CDH22 Biologics Sequence Review Report 2026: Cadherin-22 Similarity and Patent-Risk Signals
8 min read
CDH22 Biologics Sequence Review Report 2026: Cadherin-22 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CDH22 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CDH17 Biologics Sequence Review Report 2026: Cadherin-17 Similarity and Patent-Risk Signals
8 min read
CDH17 Biologics Sequence Review Report 2026: Cadherin-17 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CDH17 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →